HELSINKI AND STOCKHOLM, September 19, 2017. Aplagon Oy (“Aplagon”) and Cadila Pharmaceuticals Sweden AB today announced a development and commercialization agreement for Aplagon’s lead APAC product. APACs are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury. Under the agreement, Cadila Pharmaceuticals Sweden AB together with its parent company Cadila Pharmaceuticals Limited, […]
This author has yet to write their bio.Meanwhile lets just say that we are proud aplagoncom contributed a whooping 2 entries.
Entries by aplagoncom
17 November 2017
Onet debis dunt vene
Website by Instinctif Partners
Biomedicum Helsinki 2B
Tukholmankatu 8 B, 00290 Helsinki, Finland